Highly purified CD271+ MSCs isolated from low-risk MDS (LR-MDS) patients have the ability to fully activate the inflammatory response, which involves NF-κB, EGF, TGF-β, and TNF signaling (42). The gene discussed is NFKB1; the disease is myelodysplastic syndrome.